The present analysis aimed at assessing the independent association of BMI versus surrogate measures of central adiposity (including both WHtR and ABSI) with death from any cause in the large cohort of well-characterized individuals with type 2 diabetes from the Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicentre Study, which allows accounting for several potential sources of bias (Cardiovascular Diabetology)
Diabetes News
Tag: Type 2 Diabetes
Longitudinal changes in vitamin D concentrations and the association with type 2 diabetes mellitus: the Tromsø Study
25(OH)D concentrations seem to be affected by disease progression and type 2 diabetes diagnosis (Acta Diabetologica)
Validation of a Risk Prediction Model for Early Chronic Kidney Disease in Patients with Type 2 Diabetes: Data from the German/Austrian DPV Registry
The predictive model achieved moderate discrimination but good calibration in a German/Austrian T2D population suggesting that the model may be relevant for determining CKD risk (Diabetes, Obesity and Metabolism)
Oral Insulin (ORMD-0801) in Type 2 Diabetes Mellitus: Dose-Finding 12-Week Randomized Placebo-Controlled Study
Oral insulin (ORMD-0801) induced greater reductions in HbA1c when compared to placebo and was safe and well-tolerated in individuals with uncontrolled T2DM (Institute of Endocrinology, Metabolism & Hypertension )
Care processes in people in remission from type 2 diabetes: A cohort study using the National Diabetes Audit
People coded with remission of type 2 diabetes were less likely to receive diabetes care processes than those without such coding (Diabetic Medicine)
An Indirect Comparison of Basal Insulin Plus Once-Weekly Semaglutide and Fully Optimised Basal–Bolus Insulin in Type 2 Diabetes
In T2D uncontrolled by basal insulin, intensification with semaglutide 1.0 mg OW was associated with better glycaemic control, weight loss, and reduced hypoglycaemia versus a basal–bolus regimen, while limiting the treatment burden associated with frequent injections. Clinicians could consider treatment intensification with semaglutide when T2D is uncontrolled by basal insulin, especially when weight management is a priority (Diabetes Therapy)
Mounjaro
The European Medicines Agency therefore decided that Mounjaro’s benefits are greater than its risks and it can be authorised for use in the EU
Prognostic value of creatinine-to-cystatin c ratio in patients with type 2 diabetes mellitus: a cohort study
Low muscle mass assessed by Scr/Scys was associated with increased risk of long-term all-cause mortality in diabetic patients (Diabetology & Metabolic Syndrome)
A personalized multi-interventional approach focusing on customized nutrition, progressive fitness, and lifestyle modification resulted in the reduction of HbA1c, fasting blood sugar and weight in type 2 diabetes
The findings indicate that a comprehensive and multi-interventional diabetes care program involving personalized nutrition, fitness, and lifestyle modification such as SDRP, help in significant and sustained improvements in HbA1c level, glycaemic control, and weight loss in adults with type 2 diabetes (BMC Endocrine Disorders)
Screening all older adults aged 40-70 years would find undiagnosed type 2 diabetes cases at least two years earlier
Our study provides the first population-based estimate of the impact of HbA1c-based screening on reducing the time to diabetes diagnosis. In UK Biobank (Diabetologia )
The Platelet-to-Lymphocyte Ratio Predicts Diabetic Retinopathy in Type 2 Diabetes Mellitus
Our findings suggest that PLR may be an independent risk factor for evaluating DR in type 2 diabetes patients (Diabetes, Metabolic Syndrome and Obesity)
Safety and Efficacy of an Oral Insulin (Capsulin) in Patients with Early-Stage Type 2 Diabetes: A Dose-Ranging Phase IIb Study
Capsulin oral insulin administered twice per day at a dose of 150iu per capsule is safe, with no confirmed treatment-linked hypoglycaemic events, and results in significant decreases from baseline in HbA1c, Fasting Plasma Glucose and triglycerides (Diabetes, Obesity and Metabolism)
Pathophysiology of type 2 diabetes in sub-Saharan Africans
In this review, we summarise the existing knowledge base and data from the only non-pharmacological intervention that explores the pathophysiology of type 2 diabetes in SSA (Diabetologia)
Management of hyperglycaemia in type 2 diabetes, 2022
A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (Diabetologia)
Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials
In addition to the established cardiovascular benefits of SGLT2 inhibitors, the randomised data support their use for modifying risk of kidney disease progression and acute kidney injury, not only in patients with type 2 diabetes at high cardiovascular risk, but also in patients with chronic kidney disease or heart failure irrespective of diabetes status, primary kidney disease, or kidney function (The Lancet)
Long-term Outcomes Among Young Adults With Type 2 Diabetes Based on Durability of Glycemic Control: Results From the TODAY Cohort Study
Higher baseline HbA1c concentration and FG variability during year 1 accurately predicted youth with T2D who will experience metabolic decompensation and comorbidities. These values may be useful tools for clinicians when considering early intensification of therapy (Diabetes Care)
Novel antihyperglycaemic drugs and prevention of chronic obstructive pulmonary disease exacerbations among patients with type 2 diabetes: population based cohort study
In this population based study, GLP-1 receptor agonists and SGLT-2 inhibitors were associated with a reduced risk of severe exacerbations compared with sulfonylureas in patients with chronic obstructive pulmonary disease and type 2 diabetes. DPP-4 inhibitors were not clearly associated with a decreased risk of chronic obstructive pulmonary disease exacerbations (BMJ)
Predictors of acarbose therapeutic efficacy in newly diagnosed type 2 diabetes mellitus patients in China
Acarbose may be more effective in newly diagnosed T2DM patients with low FPG, low 2 h PG and obesity. The earlier T2DM is diagnosed and continuously treated with acarbose, the better the response to therapy (BMC Pharmacology and Toxicology)
LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial
In this early phase study, LY3437943 showed an acceptable safety profile, and its pharmacokinetics suggest suitability for once-weekly dosing. This finding, together with the pharmacodynamic findings of robust reductions in glucose and bodyweight, provides support for phase 2 development (The Lancet)
Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial
Our analysis suggests that in people with type 2 diabetes and high cardiovascular risk, tirzepatide slowed the rate of eGFR decline and reduced UACR in clinically meaningful ways compared with insulin glargine (The Lancet Diabetes & Endocrinology)
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 68
- Next Page »
Glycosmedia is also available as an App: